Hereditary Angioedema Pipeline Assessment | Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Key Companies - KalVista (KVD824), Pharvaris (PHA121), BioMarin Pharmaceutical (BMN 331)

As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 30+ pipeline drugs in the Hereditary Angioedema therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Hereditary Angioedema Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hereditary Angioedema Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Hereditary Angioedema Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Hereditary Angioedema Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hereditary Angioedema treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hereditary Angioedema market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

DelveInsight's Report covers around 30+ products under different phases of clinical development like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I), along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Hereditary Angioedema Therapeutics Analysis
Globally, there are approx. 20+ key companies developing therapies for Hereditary angioedema. Currently, KalVista Pharmaceuticals has its Hereditary angioedema drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Hereditary Angioedema Therapeutics Market include:
• BioCryst Pharmaceuticals
• KalVista Pharmaceuticals
• Pharvaris
• BioMarin Pharmaceutical
• Ionis Pharmaceuticals, Inc.
• Intellia Therapeutics
And many others

Hereditary Angioedema Drugs Covered in the report include:
• KVD900: KalVista Pharmaceuticals
• PHA121: Pharvaris
• BMN 331: BioMarin Pharmaceutical
And many more

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Hereditary Angioedema Current Treatment Patterns
4. Hereditary Angioedema - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hereditary Angioedema Late Stage Products (Phase-III)
7. Hereditary Angioedema Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hereditary Angioedema Discontinued Products
13. Hereditary Angioedema Product Profiles
14. Hereditary Angioedema Key Companies
15. Hereditary Angioedema Key Products
16. Dormant and Discontinued Products
17. Hereditary Angioedema Unmet Needs
18. Hereditary Angioedema Future Perspectives
19. Hereditary Angioedema Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.